Academic Journal
View in EDS

Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.

Bibliographic Details
Title: Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
Authors: Caminati, Marco, Maule, Matteo, Benoni, Roberto, Bagnasco, Diego, Beghè, Bianca, Braido, Fulvio, Brussino, Luisa, Cameli, Paolo, Candeliere, Maria Giulia, Carpagnano, Giovanna Elisiana, Costanzo, Giulia, Crimi, Claudia, D'Amato, Mariella, Del Giacco, Stefano, Guarnieri, Gabriella, Yacoub, Mona-Rita, Micheletto, Claudio, Nicola, Stefania, Olivieri, Bianca, Pini, Laura
Source: Biomedicines; Feb2024, Vol. 12 Issue 2, p390, 11p
Subject Terms: PATIENT reported outcome measures, DUPILUMAB, ASTHMATICS, ASTHMA, PHENOTYPES, HYPEREOSINOPHILIC syndrome, NASAL polyps
Abstract: Dupilumab is currently approved for the treatment of Type 2 severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Few studies have specifically reported on dupilumab efficacy on asthma outcomes as a primary objective in a real-life setting, in patients with and without CRSwNP. Our study aimed to explore the efficacy of dupilumab on functional, inflammatory, and patient-reported outcomes in asthma patients across different disease phenotypes and severity, including mild-to-moderate asthma coexisting with CRSwNP. Data from 3, 6, and 12 months follow-up were analyzed. Asthma (FEV1%, Tiffeneau%, ACT, FeNO, oral steroid use, exacerbation rate, and blood eosinophilia) and polyposis (SNOT22, VAS, NPS) outcomes showed a rapid (3 months) and sustained (6 and 12 months) significant change from baseline, despite most of the patients achieving oral steroid withdrawal. According to the sensitivity analysis, the improvement was not conditioned by either the presence of polyposis or severity of asthma at baseline. Of note, even in the case of milder asthma forms, a significant further improvement was recorded during dupilumab treatment course. Our report provides short-, medium-, and long-term follow-up data on asthma outcomes across different diseases phenotypes and severity, contributing to the real-world evidence related to dupilumab efficacy on upper and lower airways T2 inflammation. [ABSTRACT FROM AUTHOR]
Copyright of Biomedicines is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=22279059&ISBN=&volume=12&issue=2&date=20240201&spage=390&pages=390-400&title=Biomedicines&atitle=Dupilumab%20Efficacy%20on%20Asthma%20Functional%2C%20Inflammatory%2C%20and%20Patient-Reported%20Outcomes%20across%20Different%20Disease%20Phenotypes%20and%20Severity%3A%20A%20Real-Life%20Perspective.&aulast=Caminati%2C%20Marco&id=DOI:10.3390/biomedicines12020390
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: edb
DbLabel: Complementary Index
An: 175655180
RelevancyScore: 1007
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1007.03472900391
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Caminati%2C+Marco%22">Caminati, Marco</searchLink><br /><searchLink fieldCode="AR" term="%22Maule%2C+Matteo%22">Maule, Matteo</searchLink><br /><searchLink fieldCode="AR" term="%22Benoni%2C+Roberto%22">Benoni, Roberto</searchLink><br /><searchLink fieldCode="AR" term="%22Bagnasco%2C+Diego%22">Bagnasco, Diego</searchLink><br /><searchLink fieldCode="AR" term="%22Beghè%2C+Bianca%22">Beghè, Bianca</searchLink><br /><searchLink fieldCode="AR" term="%22Braido%2C+Fulvio%22">Braido, Fulvio</searchLink><br /><searchLink fieldCode="AR" term="%22Brussino%2C+Luisa%22">Brussino, Luisa</searchLink><br /><searchLink fieldCode="AR" term="%22Cameli%2C+Paolo%22">Cameli, Paolo</searchLink><br /><searchLink fieldCode="AR" term="%22Candeliere%2C+Maria+Giulia%22">Candeliere, Maria Giulia</searchLink><br /><searchLink fieldCode="AR" term="%22Carpagnano%2C+Giovanna+Elisiana%22">Carpagnano, Giovanna Elisiana</searchLink><br /><searchLink fieldCode="AR" term="%22Costanzo%2C+Giulia%22">Costanzo, Giulia</searchLink><br /><searchLink fieldCode="AR" term="%22Crimi%2C+Claudia%22">Crimi, Claudia</searchLink><br /><searchLink fieldCode="AR" term="%22D'Amato%2C+Mariella%22">D'Amato, Mariella</searchLink><br /><searchLink fieldCode="AR" term="%22Del+Giacco%2C+Stefano%22">Del Giacco, Stefano</searchLink><br /><searchLink fieldCode="AR" term="%22Guarnieri%2C+Gabriella%22">Guarnieri, Gabriella</searchLink><br /><searchLink fieldCode="AR" term="%22Yacoub%2C+Mona-Rita%22">Yacoub, Mona-Rita</searchLink><br /><searchLink fieldCode="AR" term="%22Micheletto%2C+Claudio%22">Micheletto, Claudio</searchLink><br /><searchLink fieldCode="AR" term="%22Nicola%2C+Stefania%22">Nicola, Stefania</searchLink><br /><searchLink fieldCode="AR" term="%22Olivieri%2C+Bianca%22">Olivieri, Bianca</searchLink><br /><searchLink fieldCode="AR" term="%22Pini%2C+Laura%22">Pini, Laura</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Biomedicines; Feb2024, Vol. 12 Issue 2, p390, 11p
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22PATIENT+reported+outcome+measures%22">PATIENT reported outcome measures</searchLink><br /><searchLink fieldCode="DE" term="%22DUPILUMAB%22">DUPILUMAB</searchLink><br /><searchLink fieldCode="DE" term="%22ASTHMATICS%22">ASTHMATICS</searchLink><br /><searchLink fieldCode="DE" term="%22ASTHMA%22">ASTHMA</searchLink><br /><searchLink fieldCode="DE" term="%22PHENOTYPES%22">PHENOTYPES</searchLink><br /><searchLink fieldCode="DE" term="%22HYPEREOSINOPHILIC+syndrome%22">HYPEREOSINOPHILIC syndrome</searchLink><br /><searchLink fieldCode="DE" term="%22NASAL+polyps%22">NASAL polyps</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Dupilumab is currently approved for the treatment of Type 2 severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). Few studies have specifically reported on dupilumab efficacy on asthma outcomes as a primary objective in a real-life setting, in patients with and without CRSwNP. Our study aimed to explore the efficacy of dupilumab on functional, inflammatory, and patient-reported outcomes in asthma patients across different disease phenotypes and severity, including mild-to-moderate asthma coexisting with CRSwNP. Data from 3, 6, and 12 months follow-up were analyzed. Asthma (FEV1%, Tiffeneau%, ACT, FeNO, oral steroid use, exacerbation rate, and blood eosinophilia) and polyposis (SNOT22, VAS, NPS) outcomes showed a rapid (3 months) and sustained (6 and 12 months) significant change from baseline, despite most of the patients achieving oral steroid withdrawal. According to the sensitivity analysis, the improvement was not conditioned by either the presence of polyposis or severity of asthma at baseline. Of note, even in the case of milder asthma forms, a significant further improvement was recorded during dupilumab treatment course. Our report provides short-, medium-, and long-term follow-up data on asthma outcomes across different diseases phenotypes and severity, contributing to the real-world evidence related to dupilumab efficacy on upper and lower airways T2 inflammation. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label:
  Group: Ab
  Data: <i>Copyright of Biomedicines is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=175655180
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3390/biomedicines12020390
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 390
    Subjects:
      – SubjectFull: PATIENT reported outcome measures
        Type: general
      – SubjectFull: DUPILUMAB
        Type: general
      – SubjectFull: ASTHMATICS
        Type: general
      – SubjectFull: ASTHMA
        Type: general
      – SubjectFull: PHENOTYPES
        Type: general
      – SubjectFull: HYPEREOSINOPHILIC syndrome
        Type: general
      – SubjectFull: NASAL polyps
        Type: general
    Titles:
      – TitleFull: Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Caminati, Marco
      – PersonEntity:
          Name:
            NameFull: Maule, Matteo
      – PersonEntity:
          Name:
            NameFull: Benoni, Roberto
      – PersonEntity:
          Name:
            NameFull: Bagnasco, Diego
      – PersonEntity:
          Name:
            NameFull: Beghè, Bianca
      – PersonEntity:
          Name:
            NameFull: Braido, Fulvio
      – PersonEntity:
          Name:
            NameFull: Brussino, Luisa
      – PersonEntity:
          Name:
            NameFull: Cameli, Paolo
      – PersonEntity:
          Name:
            NameFull: Candeliere, Maria Giulia
      – PersonEntity:
          Name:
            NameFull: Carpagnano, Giovanna Elisiana
      – PersonEntity:
          Name:
            NameFull: Costanzo, Giulia
      – PersonEntity:
          Name:
            NameFull: Crimi, Claudia
      – PersonEntity:
          Name:
            NameFull: D'Amato, Mariella
      – PersonEntity:
          Name:
            NameFull: Del Giacco, Stefano
      – PersonEntity:
          Name:
            NameFull: Guarnieri, Gabriella
      – PersonEntity:
          Name:
            NameFull: Yacoub, Mona-Rita
      – PersonEntity:
          Name:
            NameFull: Micheletto, Claudio
      – PersonEntity:
          Name:
            NameFull: Nicola, Stefania
      – PersonEntity:
          Name:
            NameFull: Olivieri, Bianca
      – PersonEntity:
          Name:
            NameFull: Pini, Laura
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 22279059
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Biomedicines
              Type: main
ResultId 1